Drug target identification

Last updated: 2021 Sep 5
Total hit(s): 2
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
15 DEGs were identified which were identified as potential therapeutic targets against COVID-19, which were related to 46 FDA approved or clinical trial drugs. 3 of them (ALP,CXCL8, IL6) were already targeted in patients infected with SARS-CoV-2 with an additional 35 drugs that target these proteins but have not been tested against the disease. 4 novel potential targets ( CCL20, CSF3, CXCL10) were identified with 6 existing drugs that could be repurposed. 8 further targets ( CXCL6, IFI44, IFI44L, RSAD2, S100A8, SPRR2A, SYNE1, XAF1) associated with the disease were identified but drugs targeting these are under clinical trial or is approved for another indication.
✍
 		Pre-print (medRXiv)
Title Drug Repurposing of potential drug targets for treatment of COVID-19
Impact factor
N/A
Date of Entry 2021 Sep 5

Comparative In silico analyses of SARS-CoV-2 genomic features (codon, codon pair, dinucleotide usage, and RNA structure around the frameshift region) was performed to find out the best potential target gene for codon pair deoptimization. Genes N and S are suggested as best targets, because of high codon pair bias (CPB) compared to that of other viral genes. 5,064 complete SARS-CoV-2 genomes were analyzed The codon and codon pair usage was calculated for all the genes coded by SARS-CoV-2. Relative synonymous codon usage (RSCU) and codon pair score (CPS) are the metrics that describe the codon and codon pair usage bias, respectively. The codon pair bias (CPB) is the average CPS across a gene.
✍
 		32973171
(Sci Rep)
PMID
32973171
Date of Publishing: 2020 Sep 24
Title Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
Author(s) nameKames J, Holcomb DD et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 22